Literature DB >> 28275579

Factors Influencing Surveillance for Hepatocellular Carcinoma in Patients with Liver Cirrhosis.

Hager A Ahmed Mohammed1, Ju Dong Yang1, Nasra H Giama1, Jonggi Choi1, Hawa M Ali1, Kristin C Mara2, William S Harmsen2, Russell H Wiesner1, Michael D Leise1, Terry M Therneau2, Lewis R Roberts1.   

Abstract

OBJECTIVE: Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related mortality worldwide, and a rising cause of cancer mortality in the U.S. Liver cirrhosis is the major risk factor for HCC. Surveillance of persons with cirrhosis facilitates early detection and improves outcomes. We assessed the surveillance rate for HCC within a major academic health system and identified factors influencing surveillance. PATIENTS AND METHODS: We examined the surveillance rate for HCC using liver ultrasound, CT, or MRI, and factors influencing surveillance in a cohort of 369 Minnesota residents with cirrhosis seen at the Mayo Clinic between 2007 and 2009.
RESULTS: Ninety-three percent of cirrhosis patients received at least one surveillance study, but only 14% received the recommended uninterrupted semiannual surveillance. Thirty percent received ≥75% of recommended surveillance, and 59% received ≥50% of recommended surveillance. Factors increasing surveillance included gastroenterology or hepatology specialist visits (p < 0.0001), advanced liver disease as assessed by hepatic encephalopathy (p = 0.0008), and comorbid illness as assessed by diabetes mellitus (p = 0.02). Age, sex, race, residence, cirrhosis etiology, or number of primary care visits did not significantly affect the rate of surveillance.
CONCLUSIONS: While the rate of surveillance in a major academic health system was higher than reported in other studies, surveillance was heavily dependent on visits to a subspecialist. This suggests a major and urgent national need to improve identification of individuals at risk for HCC in the primary care setting and the initiation and maintenance of surveillance by primary care practitioners.

Entities:  

Keywords:  Cirrhosis; Hepatocellular carcinoma; Liver cancer; Surveillance/screening

Year:  2016        PMID: 28275579      PMCID: PMC5340216          DOI: 10.1159/000450833

Source DB:  PubMed          Journal:  Liver Cancer        ISSN: 1664-5553            Impact factor:   11.740


  17 in total

Review 1.  Alcoholic liver disease.

Authors:  Robert S O'Shea; Srinivasan Dasarathy; Arthur J McCullough
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

Review 2.  Hepatocellular carcinoma: A global view.

Authors:  Ju Dong Yang; Lewis R Roberts
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-07-13       Impact factor: 46.802

Review 3.  Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review.

Authors:  Amit G Singal; Adam Yopp; Celette S Skinner; Milton Packer; William M Lee; Jasmin A Tiro
Journal:  J Gen Intern Med       Date:  2012-01-04       Impact factor: 5.128

4.  Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States.

Authors:  Jessica A Davila; Robert O Morgan; Peter A Richardson; Xianglin L Du; Katherine A McGlynn; Hashem B El-Serag
Journal:  Hepatology       Date:  2010-07       Impact factor: 17.425

Review 5.  Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace.

Authors:  György Baffy; Elizabeth M Brunt; Stephen H Caldwell
Journal:  J Hepatol       Date:  2012-02-09       Impact factor: 25.083

6.  Surveillance for hepatocellular carcinoma: how can we do better?

Authors:  Molly Hassett; Adam C Yopp; Amit G Singal
Journal:  Am J Med Sci       Date:  2013-10       Impact factor: 2.378

7.  Low adherence of HIV providers to practice guidelines for hepatocellular carcinoma screening in HIV/hepatitis B coinfection.

Authors:  Bevin Hearn; Rachel Chasan; Kian Bichoupan; Maria Suprun; Emilia Bagiella; Douglas T Dieterich; Ponni Perumalswami; Andrea D Branch; Shirish Huprikar
Journal:  Clin Infect Dis       Date:  2015-08-03       Impact factor: 9.079

8.  Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States.

Authors:  Manal M Hassan; Adam Frome; Yehuda Z Patt; Hashem B El-Serag
Journal:  J Clin Gastroenterol       Date:  2002-09       Impact factor: 3.062

9.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

10.  Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study.

Authors:  Joong-Won Park; Minshan Chen; Massimo Colombo; Lewis R Roberts; Myron Schwartz; Pei-Jer Chen; Masatoshi Kudo; Philip Johnson; Samuel Wagner; Lucinda S Orsini; Morris Sherman
Journal:  Liver Int       Date:  2015-03-25       Impact factor: 5.828

View more
  12 in total

1.  Should AFP (or any biomarkers) be used for HCC surveillance?

Authors:  Hager F Ahmed Mohammed; Lewis R Roberts
Journal:  Curr Hepatol Rep       Date:  2017-04-28

2.  Hepatocellular Carcinoma Screening Is Associated With Increased Survival of Patients With Cirrhosis.

Authors:  Debra T Choi; Hye-Chung Kum; Sulki Park; Robert L Ohsfeldt; Yu Shen; Neehar D Parikh; Amit G Singal
Journal:  Clin Gastroenterol Hepatol       Date:  2018-10-26       Impact factor: 11.382

3.  Harms of hepatocellular carcinoma surveillance.

Authors:  Jan Petrasek; Amit G Singal; Nicole E Rich
Journal:  Curr Hepatol Rep       Date:  2019-10-15

Review 4.  Patient-, Provider-, and System-Level Barriers to Surveillance for Hepatocellular Carcinoma in High-Risk Patients in the USA: a Scoping Review.

Authors:  Eliza W Beal; Mackenzie Owen; Molly McNamara; Ann Scheck McAlearney; Allan Tsung
Journal:  J Gastrointest Cancer       Date:  2022-07-26

5.  B-Mode Ultrasonography versus Contrast-Enhanced Ultrasonography for Surveillance of Hepatocellular Carcinoma: A Prospective Multicenter Randomized Controlled Trial.

Authors:  Masatoshi Kudo; Kazuomi Ueshima; Yukio Osaki; Masashi Hirooka; Yasuharu Imai; Kazunobu Aso; Kazushi Numata; Masayuki Kitano; Takashi Kumada; Namiki Izumi; Yasukiyo Sumino; Chikara Ogawa; Kohei Akazawa
Journal:  Liver Cancer       Date:  2019-06-06       Impact factor: 11.740

6.  IL-6 and NFE2L2: A putative role for the hepatoprotective effect of N. Sativa, P. Ginseng and C. Sempervirens in AFB-1 induced hepatocellular carcinoma in rats.

Authors:  Nora M Aborehab; Nermien E Waly
Journal:  Toxicol Rep       Date:  2019-05-21

7.  A Telephone and Mail Outreach Program Successfully Increases Uptake of Hepatocellular Carcinoma Surveillance.

Authors:  Elizabeth S Aby; Adam C Winters; Jonathan Lin; Aileen Bui; Jenna Kawamoto; Matthew B Goetz; Debika Bhattacharya; Joseph R Pisegna; Folasade P May; Arpan A Patel; Jihane N Benhammou
Journal:  Hepatol Commun       Date:  2020-04-24

8.  Artificial intelligence (AI) models for the ultrasonographic diagnosis of liver tumors and comparison of diagnostic accuracies between AI and human experts.

Authors:  Naoshi Nishida; Makoto Yamakawa; Tsuyoshi Shiina; Yoshito Mekada; Mutsumi Nishida; Naoya Sakamoto; Takashi Nishimura; Hiroko Iijima; Toshiko Hirai; Ken Takahashi; Masaya Sato; Ryosuke Tateishi; Masahiro Ogawa; Hideaki Mori; Masayuki Kitano; Hidenori Toyoda; Chikara Ogawa; Masatoshi Kudo
Journal:  J Gastroenterol       Date:  2022-02-27       Impact factor: 7.527

9.  Effect of Hepatocellular Carcinoma Surveillance Programmes on Overall Survival in a Mixed Cirrhotic UK Population: A Prospective, Longitudinal Cohort Study.

Authors:  Mohammad Inamul Haq; Thomas M Drake; Tee Lin Goh; Asma Ahmed; Ewan Forrest; Stephen Barclay; Ruth Gillespie; Mathew Priest; Jeff Evans; Janet Graham; Stuart Ballantyne; Donald C McMillan; Peter C Hayes; Thomas G Bird; Adrian J Stanley
Journal:  J Clin Med       Date:  2021-06-24       Impact factor: 4.241

10.  Gender differences in hepatocellular cancer: disparities in nonalcoholic fatty liver disease/steatohepatitis and liver transplantation.

Authors:  Eric M Wu; Linda L Wong; Brenda Y Hernandez; Jun-Fang Ji; Wei Jia; Sandi A Kwee; Sumodh Kalathil
Journal:  Hepatoma Res       Date:  2018-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.